Shenzhen Jiji Love Medical Technology Co., LTD. – Trademark Portfolio
Entity Type: 99
Shenzhen Jiji Love Medical Technology Co., LTD. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 25 (Clothing) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include JJICN. The owner is based in Luohu Dist, Shenzhen.
Dongchang Rd, Dongxiao Community,
1409, Unit 2, Jindi Mingyuan, No. 2,
Luohu Dist, Shenzhen 518000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Shenzhen Jiji Love Medical Technology Co., LTD.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Shenzhen Jiji Love Medical Technology Co., LTD. have?
Shenzhen Jiji Love Medical Technology Co., LTD. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does Shenzhen Jiji Love Medical Technology Co., LTD. file in?
Shenzhen Jiji Love Medical Technology Co., LTD. files trademarks across 2 Nice Classification classes. The most active classes are Class 25 (Clothing), Class 5 (Pharmaceuticals). Class 25 covers clothing, footwear, headgear.
What are Shenzhen Jiji Love Medical Technology Co., LTD.'s most well-known trademarks?
Shenzhen Jiji Love Medical Technology Co., LTD.'s registered trademark portfolio includes well-known marks such as JJICN. These are among 2 currently registered trademarks in the portfolio.
What is Shenzhen Jiji Love Medical Technology Co., LTD.'s trademark registration success rate?
Shenzhen Jiji Love Medical Technology Co., LTD. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.